David M. Stack Sells 25,000 Shares of Pacira Pharmaceuticals Inc. (PCRX) Stock

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) CEO David M. Stack sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $33.79, for a total value of $844,750.00. Following the completion of the transaction, the chief executive officer now owns 115,446 shares in the company, valued at $3,900,920.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of PCRX stock opened at $34.90 on Friday. Pacira Pharmaceuticals Inc. has a 12-month low of $26.95 and a 12-month high of $51.10. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 1.00.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, May 3rd. The company reported $0.02 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02. Pacira Pharmaceuticals had a negative return on equity of 5.81% and a negative net margin of 11.45%. The company had revenue of $74.61 million for the quarter, compared to analysts’ expectations of $73.92 million. During the same period in the previous year, the firm posted ($0.19) earnings per share. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. sell-side analysts anticipate that Pacira Pharmaceuticals Inc. will post -0.57 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE increased its stake in Pacira Pharmaceuticals by 53.8% during the first quarter. US Bancorp DE now owns 4,292 shares of the company’s stock worth $134,000 after acquiring an additional 1,501 shares during the last quarter. Fisher Asset Management LLC increased its stake in Pacira Pharmaceuticals by 29.6% during the first quarter. Fisher Asset Management LLC now owns 6,848 shares of the company’s stock worth $213,000 after acquiring an additional 1,566 shares during the last quarter. Mizuho Securities USA LLC increased its stake in Pacira Pharmaceuticals by 20.8% during the fourth quarter. Mizuho Securities USA LLC now owns 9,300 shares of the company’s stock worth $425,000 after acquiring an additional 1,600 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in Pacira Pharmaceuticals by 1.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 152,857 shares of the company’s stock worth $6,978,000 after acquiring an additional 1,779 shares during the last quarter. Finally, California Public Employees Retirement System increased its stake in Pacira Pharmaceuticals by 3.3% during the fourth quarter. California Public Employees Retirement System now owns 68,100 shares of the company’s stock worth $3,109,000 after acquiring an additional 2,200 shares during the last quarter.

Several equities analysts have recently commented on PCRX shares. Wedbush lowered their price objective on Pacira Pharmaceuticals from $72.00 to $80.00 and set an “outperform” rating on the stock in a research report on Monday, April 9th. JPMorgan Chase restated a “hold” rating and issued a $43.00 price objective (up from $40.00) on shares of Pacira Pharmaceuticals in a research report on Monday, April 9th. Seaport Global Securities restated a “buy” rating and issued a $42.00 price objective on shares of Pacira Pharmaceuticals in a research report on Tuesday, March 20th. Mizuho lowered their price objective on Pacira Pharmaceuticals from $44.00 to $31.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 21st. Finally, BMO Capital Markets lowered their price objective on Pacira Pharmaceuticals from $41.00 to $32.00 and set a “market perform” rating on the stock in a research report on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $45.00.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply